Drug Price Regulation
Drug prices are regulated in a legal framework that organizes the negotiation between pharmaceutical firms and a third-party payer responsible for healthcare reimbursement. This regulation aims at compensating for market failures associated with drug specificities. Explicit economic reasoning through the so-called health technology assessment framework is increasingly embedded in the institutional and administrative process of the evaluation procedure leading to market access, pricing and reimbursement for new drugs.
KeywordsHealth Technology Assessment Drug Price National Health Insurance Scheme Sickness Fund Pharmaceutical Firm
- Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941–973Google Scholar
- Drummond M, Sculpher M, Claxton K, Stoddart G , Torrance G (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, New YorkGoogle Scholar
- Hurley J (2000) An overview of the normative economics of the health sector. In: Culyer A, Newhouse J (eds) Handbook of health economics. Elsevier, Amsterdam, pp 55–118Google Scholar
- Morris S, Devlin N, Parkin D (2007) Economic analysis in health care. Wiley, New YorkGoogle Scholar
- Rice T, Rosenau P, Unruh L, Barnes A, Saltman R, van Ginneken E (2013) United States of America: health system review. Health Syst Transit 15:70–80Google Scholar